Martina McAteer (Duric)

Martina McAteer obtained her BSc (Hons) degree from The Queen’s University Belfast, MSc from the University of Aberdeen and PhD in Nutritional Biochemistry from the University of Nottingham.  She undertook postdoctoral positions at the University of Oxford in the Diabetes Genetics Group (2000-2002) and in the Division of Cardiovascular Medicine (2002-2013) where her research focused on the development of novel nanoparticle contrast agents for molecular magnetic resonance imaging  (MRI) of vascular inflammatory diseases including atherosclerosis, multiple sclerosis and cancer. 

Martina joined the nanomedicine company Midatech Pharma Plc, Abingdon, UK (2013-2019) as Translational Science Programme Manager and Head of Immunotherapy, where she led immunotherapy programmes focused on the development of gold nanoparticle-based immunotherapies for autoimmune diseases and oncology. She played a key role in the EE-ASI Consortium aimed at clinically testing an innovative vaccine for Type 1 diabetes and the Eurostars PAT (psoriasis anti-inflammatory treatment) programme working closely with partners across the UK and Europe.

Martina joined the Department of Oncology in August 2019 as Project Manager and Engagement Coordinator for the National Cancer Imaging Translational Accelerator (NCITA) programme, working with Geoff Higgins and Katherine Vallis at Oxford.  The NCITA network includes nine world-leading UK medical imaging centres at the University of Oxford, University College London, University of Manchester, King’s College London, The Institute of Cancer Research, London, and The Royal Marsden NHS Foundation Trust, Imperial College London, Cambridge University, Newcastle University and University of Glasgow

To read more about NCITA, see the Comment Article published in the British Journal of Cancer on 27 July 2021.  View also the NCITA blog 'Delivering high quality clinical imaging research' published by the Association of Medical Research Charities (AMRC) on 22 September 2021 and the article 'Advancing imaging biomarker development and translation through the National Cancer Imaging Translational Accelerator (NCITA)' published in Research Outreach on 7 February 2022.